Review highlights advances in targeted nanocarriers for central nervous system drug delivery, indicating enhanced therapeutic precision for depression.
Key Points
To evaluate recent advancements in nanomedicine and engineered nanoplatforms aimed at overcoming the pharmacokinetic limitations of conventional antidepressant therapies.
Reviewed literature on nanotechnology-based central nervous system drug delivery systems, focusing on lipid-based and polymeric nanocarriers.
Analyzed mechanisms enhancing blood–brain barrier permeation, bioavailability, and targeted drug release kinetics in depression models.
Engineered nanocarriers improved drug stability, extended systemic circulation time, and facilitated enhanced transport across the blood–brain barrier.
Lipid-based and polymeric nanoparticles enabled controlled, site-specific drug release while directly modulating pathological pathways associated with depression.
Identified critical translational barriers that require further investigation, specifically regarding biocompatibility, scalable manufacturing, and clinical safety profiles.